Tina Shah, MD
Rheumatology · Kansas City, MONPI 1972766368
Payments from drug & device makers
Across 182 payments — averaging $6475.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$429K
- Amgen$281K
- Novartis$218K
- UCB SA$105K
- Eli Lilly$78K
- Johnson & Johnson$22K
- plus $45K from 9 others
Across 14 payments — averaging $3670.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$50K
- AbbVie$1K
What the payments were for
- Consulting fees$14,63041%
- Speaking & faculty fees$14,96442%
- Travel & lodging$4,38712%
- Food & beverage$1,7825%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $428,719 |
| Amgen | 21 | $280,685 |
| Novartis | 5 | $218,173 |
| UCB SA | 5 | $105,331 |
| Eli Lilly | 3 | $78,091 |
| Johnson & Johnson | 30 | $22,185 |
| Janssen Research & Development, LLC | 2 | $18,712 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17,541 |
| UCB, Inc. | 17 | $8,696 |
| Janssen Scientific Affairs, LLC | 8 | $215 |
| Organon | 3 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| AstraZeneca | 1 | $43 |
| Merck | 1 | $26 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$20,714
- SIMPONI ARIA$19,460
- Bimzelx$8,192
- Rinvoq$4,320
How this compares
$1,178,579 in reported general payments places this provider in the 95th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 31 | $254,335 |
| Humira PenAdalimumab | 13 | $87,096 |
| Enbrel SureclickEtanercept | 12 | $86,328 |
| KevzaraSarilumab | 16 | $71,575 |
| Hydroxychloroquine Sulfate | 710 | $34,629 |
| MethotrexateMethotrexate Sodium | 488 | $17,742 |
| Mycophenolate Mofetil | 30 | $6,748 |
| Sulfasalazine | 139 | $4,301 |
| Prednisone | 436 | $3,440 |
| Duloxetine Hcl | 114 | $2,834 |
| Celecoxib | 73 | $2,277 |
| Sulfasalazine DrSulfasalazine | 24 | $1,572 |
| Gabapentin | 88 | $1,512 |
| Cyclobenzaprine Hcl | 121 | $1,475 |
| Leflunomide | 34 | $1,359 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Kansas City
- John ErvinKansas City$18.7M
- Ghaith NoaisehKansas City$1.6M
- Mark BoxKansas City$396K
- Thomas ScottKansas City$48K
- David JohnKansas City$3K
- Julian MagadanKansas City$3K
- David TrueSpringfield$15.8M
- Anne WinklerCarthage$1.6M
- Alfred KimSaint Louis$1.2M
- Sona KamatSaint Louis$931K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.